When Christy Fennewald was 36, she felt a lump in one of her breasts, but a diagnostic ultrasound didn't pick up that it was suspicious. Nine months later, she was diagnosed with breast cancer and ...

Natera has announced the initiation of the Phase II TEODOR trial of its Signatera test aimed at replacing chemotherapy with endocrine therapy before surgery in certain breast cancer patients. The ...

My husband’s cancer came back this summer after not being evident for almost two years. With advances in cancer surveillance, we now speak of cancer survivors being cancer-free far less frequently. If ...

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the activation of the NRG Oncology trial, ARCHER (NRG-GU015), a ...

US-based clinical genetic testing company Natera said that its Signatera test will be utilised in the newly activated ARCHER trial, a Phase III study sponsored by NRG Oncology. The trial focuses on ...

AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that its personalized and tumor-informed molecular residual disease (MRD) test, ...

Stage 3 colorectal cancer patients with MRD benefit from Celebrex addition to chemotherapy, showing a 40% risk reduction in death for Signatera-positive patients. Celebrex improved disease-free and ...

Studies include nearly 25,000 patients across multiple indications, showcasing the clinical impact of Signatera Breast: 8 accepted abstracts (4 oral presentations), including interim analysis from the ...

Natera Inc. (NASDAQ: NTRA) on Wednesday revealed initial translational research results from the international randomized Phase 3 PALLAS study. Data were presented at the San Antonio Breast Cancer ...

Multi-cancer policy from BCBS of Louisiana covers CRC, Bladder, and IO monitoring AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today ...

Baseline ctDNA negativity or on-treatment clearance in anal squamous cell carcinoma correlated with 100% one-year overall survival and no local recurrence, whereas post-treatment positivity predicted ...

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that data from more than 25 Signatera studies will be presented at ...